Maternal Serum Multiple Marker Screening
for Chromosome Abnormalities and Open Neural Tube Defects:
A Fact Sheet for Practitioners

The multiple marker screening test is a screening test. It is not a diagnostic test. Multiple parameters, including maternal age, gestational age, maternal weight, and levels of one or more of the following analytes: alpha fetoprotein (AFP), human chorionic gonadotropin (hCG) and unconjugated estriol (uE3), and inhibin-A, are used to calculate a risk for a woman to have a baby with Down syndrome, trisomy 18 or a neural tube defect.

Screening for Down syndrome (DS)

- The screening uses all four analytes.
- Multiple marker screening should be offered to all pregnant women who will be under 35 years of age at delivery. Using the algorithm on the back of this page, 60-70% of babies with DS will be detected in women under 35, compared to only 20% if MSAFP is used alone. If four analytes are used, the detection rate increases significantly.
- MSAFP alone should not be used as a precursor to multiple marker screening.
- Multiple marker screening is not equivalent to diagnostic testing. Women ≥ 35 should always be offered diagnostic testing for chromosome abnormalities. However, if amniocentesis and CVS are declined, multiple marker screening may be useful to women who would like refined risk information.
- Results will be reported either in terms of second trimester risks, or risks at term. For example, a 1/270 second trimester risk for DS is equivalent to a 1/400 risk at term. Second trimester risks differ from term risks because more babies with DS than with normal chromosomes are stillborn or miscarried in the third trimester.
- Typically, it is the most reassuring to a patient to present the laboratory results in the form of a percentage rather than a fraction. For example, a 1/200 risk for DS is the same as a ½% risk, or 99 ½ % chance the baby does not have DS. Even if her risk is increased, a patient can be reassured that the odds are in her favor that her baby does not have DS.
- Recalculate risks only when the reported risk is based on menstrual or exam dating, and ultrasound dating differs from original dating by two weeks or more. The risk can be recalculated by the laboratory performing the serum screening.

Screening for Trisomy 18

- The screening uses AFP, hCG, and uE3. Estriol is the most sensitive indicator.
- Multiple marker screening may detect an increased risk for Trisomy 18.
- Screen positive results cannot be explained by incorrect dating because many fetuses with Trisomy 18 are growth retarded. Therefore, recalculating the risk of trisomy 18 because of incorrect dates is not recommended.

Screening for Open Neural Tube Defects (ONTD)

- The screening uses alpha fetoprotein only.
- The detection rate for ONTD is 80-90% using MSAFP cut-off at 2.5 multiple of the median (MOM).
- An elevated MSAFP may be explained by incorrect dating, bleeding, multiple gestation, other anatomic defects, or a chromosome problem.
Interpreting Screening Results

To accurately interpret the results, the laboratory will need to know ethnicity, if this is a twin gestation, ultrasound dating, and if the patient has diabetes.

When the maternal serum multiple marker screen is positive, genetic counseling and prenatal diagnosis should be offered. Unexplained hCG and/or MSAFP elevations may be associated with adverse perinatal outcome including: preeclampsia, premature labor, low birth weight, placental abruption or stillbirth. Follow up ultrasound an/or perinatal consult should be considered.

Each laboratory may have its own interpretation for what is considered screen positive. Please consult with the testing laboratory regarding their screening parameters.

Remember, maternal serum multiple marker screening is not a diagnostic test.

Please see page 3 for an algorithm and a list of prenatal genetics clinics in the Pacific Northwest.

This fact sheet is available from:
Pacific Northwest Regional Genetics Group
pacnorgg@oregon.uoregon.edu
http://mchneighborhood.ichp.edu/pacnorgg
Maternal Serum Multiple Marker Screening Algorithm for Practitioners

- Maternal age < 34 at delivery
  - Offer Multiple Marker Screening between 15-20 weeks GA
  - Informed consent
  - Screen negative
  - Screen positive

  - Risk not increased above predetermined cut-off
    - No further follow-up indicated
    - Increased risk Down syndrome
    - Increased risk ONTD
    - Increased risk trisomy 18

- Dating incorrect, but revised GA between 15-20 weeks at time of draw
  - Recalculate risk
- Dating incorrect GA <15 wks at time of draw
  - Redraw between 15-20 wks
- Dating incorrect GA>20 wks at time of draw
  - Test may be invalid

*All women ≥ 35 at delivery should receive genetic counseling to discuss their options regarding diagnostic testing vs. multiple marker screening.

Please consult with the testing laboratory regarding their screening parameters, specimen handling, and test availability.

Source: consensus of the PacNoRGG Prenatal Genetics committee

Where can I get further information?

Prenatal Genetics Clinics in the Pacific Northwest

**ALASKA**
- Anchorage
  - Providence Hospital, 907/261-3097

**IDAHO**
- Boise
  - St. Luke’s Hospital, 208/381-3088

**OREGON**
- Eugene
  - Center for Genetics and Maternal Fetal Medicine, 541/349-7600

  - Portland
    - Kaiser Permanente NW, 503/331-6593
    - Legacy Emanuel Hospital & Health Center, 503/413-4726
    - Northwest Perinatal Center, 503/297-3660
    - Oregon Health and Science University, 503/494-7577

**WASHINGTON**
- Bellevue
  - Eastside Maternal-Fetal Medicine, 425/688-8111

- Kirkland
  - Evergreen Hospital Maternal-Fetal Medicine, 425/899-2200

- Renton
  - Perinatal Obstetrics Medical Group, Inc., 425/656-5520

- Seattle
  - Swedish Medical Center, 206/386-2101
  - University of Washington Medical Center, 206/598-8130

- Spokane
  - Inland Northwest Genetics Clinic, 509/473-7115

- Tacoma
  - Madigan Army Medical Center, 253/968-1252
  - Prenatal Appts., Consult for Reproductive Genetics
  - 253/968-1160
  - Obstetrics Medical Group of Washington, Inc., 253/552-1037

- Walla Walla
  - Blue Mountain Genetics Clinic, 509/525-1302

- Wenatchee
  - Central Washington Hospital Genetics Group, 509/667-3350

- Yakima
  - Yakima Valley Memorial Hospital, 509/575-8160

This fact sheet is available from:

Pacific Northwest Regional Genetics Group

http://mchnneighborhood.ichp.edu/pacnorgg

The Pacific Northwest Regional Genetics Group (PacNoRGG) is funded by project MCJ-411002-12 of the Maternal and Child Health Bureau, Dept of Health and Human Services. Developed by the PacNoRGG Prenatal Genetics committee. Reviewed 2002